{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:49:14Z","timestamp":1790488154093,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004588","name":"Istituto Pasteur-Fondazione Cenci Bolognetti","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"University of Rome La Sapienza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejmech.2021.113532","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T02:17:19Z","timestamp":1620181039000},"page":"113532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia"],"prefix":"10.1016","volume":"221","author":[{"given":"Michela","family":"Puxeddu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Coluccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Bufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Nalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Da Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tremolanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stefania","family":"Sinicropi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ceramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Iacopetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata Maria Luce","family":"Coluccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"La Regina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113532_bib1","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.18632\/oncotarget.23476","article-title":"Glioblastoma: new therapeutic strategies to address cellular and genomic complexity","volume":"9","author":"Cai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113532_bib2","first-page":"7910754","article-title":"Brain tumors: rise in glioblastoma incidence in England 1995-2015 suggests an adverse environmental or lifestyle factor","author":"Philips","year":"2018","journal-title":"J.\u00a0Environ. Public Health"},{"key":"10.1016\/j.ejmech.2021.113532_bib3","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejmech.2021.113532_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11060-019-03339-0","article-title":"First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide","volume":"146","author":"Hata","year":"2020","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113532_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/cancers12040937","article-title":"Glioblastoma: pathogenesis and current status of chemotherapy and other novel treatments","volume":"12","author":"Rajaratnam","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113532_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.biopha.2017.05.125","article-title":"Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy","volume":"92","author":"Anjum","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113532_bib7","author":"American Cancer Society"},{"key":"10.1016\/j.ejmech.2021.113532_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A\u00a0new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113532_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2021.113532_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)","volume":"57","author":"Walz","year":"2006","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.ejmech.2021.113532_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00277-006-0171-8","article-title":"Not all imatinib resistance in CML are BCR-ABL kinase domain mutations","volume":"85","author":"Wei","year":"2006","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2021.113532_bib12","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113532_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-319-91439-8_5","article-title":"A\u00a0third-generation inhibitor for the treatment of CML","volume":"212","author":"Wehrle","year":"2018","journal-title":"Recent Results Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113532_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/nop\/npz001","article-title":"Second primary cancers in long-term survivors of glioblastoma","volume":"6","author":"Kim","year":"2019","journal-title":"Neuro-Oncology Practice"},{"key":"10.1016\/j.ejmech.2021.113532_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","article-title":"Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"109","author":"Sasaki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2021.113532_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/neuonc\/nop068","article-title":"Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies","volume":"12","author":"De Witt Hamer","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2021.113532_bib17","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-06-0773","article-title":"Phase I\/II study of imatinib mesylate for recurrent malignant gliomas: north American Brain Tumor Consortium Study 99-08","volume":"12","author":"Wen","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113532_bib18","doi-asserted-by":"crossref","first-page":"27378","DOI":"10.1038\/srep27378","article-title":"Imatinib and nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling","volume":"6","author":"Frolov","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113532_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113532_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cancers11030392","article-title":"Targeting the mDia formin-assembled cytoskeleton is an effective anti-invasion strategy in adult high-grade glioma patient-derived neurospheres","volume":"11","author":"Pettee","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.113532_bib21","doi-asserted-by":"crossref","first-page":"111828","DOI":"10.1016\/j.ejmech.2019.111828","article-title":"Structure-activity relationship studies and in\u00a0vitro and in\u00a0vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies","volume":"185","author":"Puxeddu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113532_bib22","series-title":"Drug-like Properties: Concepts, Structure Design, and Methods","first-page":"161","article-title":"Metabolic stability, chapter 11","author":"Di","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113532_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2021.113532_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0169-409X(95)00003-P","article-title":"Transport of small molecules through the blood-brain barrier: biology and methodology","volume":"15","author":"Pardridge","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113532_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.6-suppl_3-5","article-title":"Taxane\/anthracycline combinations: setting a new standard in breast cancer?","volume":"3","author":"Nabholtz","year":"2001","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2021.113532_bib26","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.18632\/oncotarget.3264","article-title":"Dual targeting of microtubule and topoisomerase II by \u03b1-carboline derivative YCH337 for tumor proliferation and growth inhibition","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113532_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.14791\/btrt.2014.2.1.22","article-title":"Proteomic analysis between U87MG and U343MG-A cell lines: searching for candidate proteins for glioma invasion","volume":"2","author":"Pei","year":"2014","journal-title":"Brain Tumor Res. Treat."},{"key":"10.1016\/j.ejmech.2021.113532_bib28","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1101\/gad.13.15.1899","article-title":"BCL-2 family members and the mitochondria in apoptosis","volume":"13","author":"Gross","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2021.113532_bib29","article-title":"Shail. Turcot syndrome: a synchronous clinical presentation of glioblastoma multiforme and adenocarcinoma of the colon","author":"Dipro","year":"2012","journal-title":"Case Rep. Oncol. Med."},{"key":"10.1016\/j.ejmech.2021.113532_bib30","first-page":"8516","article-title":"In\u00a0vitro analysis of putative cancer stem cell populations and chemosensitivity in the SW480 and SW620 colon cancer metastasis model","volume":"15","author":"Slater","year":"2018","journal-title":"Oncology Lett"},{"key":"10.1016\/j.ejmech.2021.113532_bib31","doi-asserted-by":"crossref","first-page":"63937","DOI":"10.18632\/oncotarget.11570","article-title":"Comparative profiling between primary colorectal carcinoma and metastases identifies heterogeneity on drug resistance","volume":"39","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113532_bib32","doi-asserted-by":"crossref","first-page":"126905","DOI":"10.1016\/j.bmcl.2019.126905","article-title":"From coins to cancer therapy: gold, silver and copper complexes targeting human topoisomerases","volume":"30","author":"Ceramella","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113532_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113532_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein-ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113532_bib35","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/acs.jcim.0c00325","article-title":"The use of methods of computer-aided drug discovery in the development of topoisomerase II inhibitors: applications and future directions","volume":"60","author":"Radaeva","year":"2020","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113532_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1204117","article-title":"Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide","volume":"6041","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113532_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2021.113532_bib38","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113532_bib39","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113532_bib40","series-title":"QikProp","author":"Schr\u00f6dinger Release 2018","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113532_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/1471-2105-9-396","article-title":"FAF-Drugs2: a free ADME\/tox filtering tool to assist drug discovery and chemical biology projects","volume":"24","author":"Lagorce","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejmech.2021.113532_bib42","author":"FAFDrugs4"},{"key":"10.1016\/j.ejmech.2021.113532_bib43","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/ci700257y","article-title":"Computation of octanol-water partition coefficients by guiding an additive model with knowledge","volume":"47","author":"Cheng","year":"2007","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113532_bib44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1021\/ci034243x","article-title":"ESOL: estimating aqueous solubility directly from molecular structure","volume":"44","author":"Delaney","year":"2004","journal-title":"J.\u00a0Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.ejmech.2021.113532_bib45","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/ja993663t","article-title":"Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water","volume":"122","author":"Duffy","year":"2000","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113532_bib46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejmech.2015.06.029","article-title":"4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in\u00a0vivo metastasis model","volume":"101","author":"Roman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113532_bib47","series-title":"Schrodinger Release 2017-3","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113532_bib48","first-page":"221e234","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2021.113532_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein-ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113532_bib50","unstructured":"The PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC."},{"key":"10.1016\/j.ejmech.2021.113532_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/CBB:38:1:1","article-title":"Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin","volume":"38","author":"Hamel","year":"2003","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.113532_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.53.1.62","article-title":"Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells","volume":"35","author":"Verdier-Pinard","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113532_bib53","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2021.113532_bib54","first-page":"197","article-title":"Attenuation of WAF1\/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin","volume":"5","author":"Ruan","year":"1999","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113532_bib55","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/acs.jmedchem.5b00310","article-title":"New indole tubulin assembly inhibitors cause stable arrest of mitotic progression, enhanced stimulation of natural killer cell cytotoxic activity, and repression of hedgehog-dependent cancer","volume":"58","author":"La Regina","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113532_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2021.113532_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-1759(91)90114-U","article-title":"An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT","volume":"142","author":"Roehm","year":"1991","journal-title":"J.\u00a0lmmun. Meth."},{"key":"10.1016\/j.ejmech.2021.113532_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejps.2016.09.039","article-title":"Multifaceted properties of 1,4-dimethylcarbazoles: focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors","volume":"96","author":"Iacopetta","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421003810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421003810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:31:57Z","timestamp":1759329117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421003810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":58,"alternative-id":["S0223523421003810"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113532","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113532"}}